TY - JOUR
T1 - Intraoperative detection of colorectal and pancreatic liver metastases using SGM-101, a fluorescent antibody targeting CEA
AU - Meijer, Ruben P. J.
AU - de Valk, Kim S.
AU - Deken, Marion M.
AU - Boogerd, Leonora S. F.
AU - Hoogstins, Charlotte E. S.
AU - Bhairosingh, Shadhvi S.
AU - Swijnenburg, Rutger-Jan
AU - Bonsing, Bert A.
AU - Framery, B. rénice
AU - Fariña Sarasqueta, Arantza
AU - Putter, Hein
AU - Hilling, Denise E.
AU - Burggraaf, Jacobus
AU - Cailler, Françoise
AU - Mieog, J. Sven D.
AU - Vahrmeijer, Alexander L.
N1 - Funding Information: This work was funded by SurgiMab (Montpellier, France). Vahrmeijer received two grants from the Dutch Cancer Society (KWF) for tumor-specific near-infrared fluorescence imaging ( UL2015-8089 and UL2018-11363 ) and Mieog received a Veni grant from the Dutch National Society for Scientific Research (ZonMW) for optical navigation in pancreatic surgery ( 91619059 ). Funding Information: This work was funded by SurgiMab (Montpellier, France). Vahrmeijer received two grants from the Dutch Cancer Society (KWF) for tumor-specific near-infrared fluorescence imaging (UL2015-8089 and UL2018-11363) and Mieog received a Veni grant from the Dutch National Society for Scientific Research (ZonMW) for optical navigation in pancreatic surgery (91619059).This work was funded by SurgiMab (Montpellier, France). The funder had no role in the conduct of the study; collection, management, analysis and interpretation of the data; and decision to submit the manuscript for publication. Quest Medical Imaging BV, Middenmeer, the Netherlands, provided the near-infrared Quest Spectrum?. Publisher Copyright: © 2020 Copyright: Copyright 2021 Elsevier B.V., All rights reserved.
PY - 2021/3
Y1 - 2021/3
N2 - Background: Fluorescence-guided surgery can provide surgeons with an imaging tool for real-time intraoperative tumor detection. SGM-101, an anti-CEA antibody labelled with a fluorescent dye, is a tumor-specific imaging agent that can aid in improving detection and complete resection for CEA-positive tumors. In this study, the performance of SGM-101 for the detection of colorectal and pancreatic liver metastases was investigated. Methods: In this open-label, non-randomized, single-arm pilot study, patients were included with liver metastases from colorectal origin and intraoperatively detected liver metastases from pancreatic origin (during planned pancreatic surgery). SGM-101 was administered two to four days before the scheduled surgery as a single intravenous injection. Intraoperative fluorescence imaging was performed using the Quest Spectrum® imaging system. The performance of SGM-101 was assessed by measuring the intraoperative fluorescence signal and comparing this to histopathology. Results: A total of 19 lesions were found in 11 patients, which were all suspected as malignant in white light and subsequent fluorescence inspection. Seventeen lesions were malignant with a mean tumor-to-background ratio of 1.7. The remaining two lesions were false-positives as proven by histology. Conclusion: CEA-targeted fluorescence-guided intraoperative tumor detection with SGM-101 is feasible for the detection of colorectal and pancreatic liver metastases.
AB - Background: Fluorescence-guided surgery can provide surgeons with an imaging tool for real-time intraoperative tumor detection. SGM-101, an anti-CEA antibody labelled with a fluorescent dye, is a tumor-specific imaging agent that can aid in improving detection and complete resection for CEA-positive tumors. In this study, the performance of SGM-101 for the detection of colorectal and pancreatic liver metastases was investigated. Methods: In this open-label, non-randomized, single-arm pilot study, patients were included with liver metastases from colorectal origin and intraoperatively detected liver metastases from pancreatic origin (during planned pancreatic surgery). SGM-101 was administered two to four days before the scheduled surgery as a single intravenous injection. Intraoperative fluorescence imaging was performed using the Quest Spectrum® imaging system. The performance of SGM-101 was assessed by measuring the intraoperative fluorescence signal and comparing this to histopathology. Results: A total of 19 lesions were found in 11 patients, which were all suspected as malignant in white light and subsequent fluorescence inspection. Seventeen lesions were malignant with a mean tumor-to-background ratio of 1.7. The remaining two lesions were false-positives as proven by histology. Conclusion: CEA-targeted fluorescence-guided intraoperative tumor detection with SGM-101 is feasible for the detection of colorectal and pancreatic liver metastases.
KW - Colorectal cancer
KW - Fluorescence-guided surgery
KW - Liver metastases
KW - Pancreatic cancer
UR - http://www.scopus.com/inward/record.url?scp=85095831735&partnerID=8YFLogxK
U2 - https://doi.org/10.1016/j.ejso.2020.10.034
DO - https://doi.org/10.1016/j.ejso.2020.10.034
M3 - Article
C2 - 33158638
SN - 0748-7983
VL - 47
SP - 667
EP - 673
JO - European Journal of Surgical Oncology
JF - European Journal of Surgical Oncology
IS - 3
ER -